MMedicsen — Pre-seed (estimated) · €250K
Medicsen closed a €250K round in April 2017 to start safety testing of its non-invasive artificial-pancreas prototype, once its intellectual-property work was done. No investors were disclosed. The company had received about $30K of early funding in 2015 to build its first minimum viable products.
Lead not disclosed
RoundPre-seed (estimated)
AnnouncedApr 2017
CityMadrid
SectorHealthtech & Bio · Healthtech / Medtech
Source
I
I
The company
Investors
No investors were disclosed for this round.